Invega
NDC 21695-455
Product Information
Invega is a NDA-approved product labeled by Rebel Distributors Corp. This medication is used to treat certain mental/mood disorders (such as schizophrenia, schizoaffective disorder). It is supplied as a brown product. This product entry covers the primary NDC 21695-455 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
PAL;6
Code Structure Chart
Product Details
What is NDC 21695-455?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PALIPERIDONE (UNII: 838F01T721)
- PALIPERIDONE (UNII: 838F01T721) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CARNAUBA WAX (UNII: R12CBM0EIZ)
- CELLULOSE ACETATE (UNII: 3J2P07GVB6)
- POLYETHYLENE GLYCOL (UNII: 3WJQ0SDW1A)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- POVIDONE (UNII: FZ989GH94E)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 672569 - paliperidone 6 MG 24HR Extended Release Oral Tablet
- RxCUI: 672569 - 24 HR paliperidone 6 MG Extended Release Oral Tablet
- RxCUI: 672569 - paliperidone 6 MG 24 HR Extended Release Oral Tablet
- RxCUI: 686443 - INVEGA 6 MG 24HR Extended Release Oral Tablet
- RxCUI: 686443 - 24 HR paliperidone 6 MG Extended Release Oral Tablet [Invega]
* Please review the full disclaimer at the bottom of this page.